Out of a total of 164 million doses administered, India has identified 26 cases of bleeding and thrombosis among people who have received AstraZeneca vaccine, the Ministry of Health stated today, characterizing the risk as “infinitesimal”.
There are countries that have suspended or limited the use of the vaccine due to fears of possible side effects, although health experts have ruled that the benefits outweigh the risks.
It is the first time that India reports any serious reaction to the use of this vaccine, which in India is called Covishield.
Competent Indian committee examined 498 cases of serious and severe side effects after vaccination, said the ministry, 26 of which were possibly “thromboembolic” – i.e. a blood clot forming in a blood vessel which could detach and close another vessel.
The ministry said The proportion of these rare cases in India is about 0.61 per million doses, compared with 4 in Britain and 10 in Germany..

“Cases of bleeding and clots “After the COVID vaccination in India, they are infinitesimal and consistent with the expected number of diagnoses of such conditions,” the ministry said in a statement, citing the commission.
The vaccine “still has a clearly positive benefit / risk profile with a huge potential to prevent infections and reduce the number of deaths due to COVID-19,” he was quoted as saying by Reuters and the Athens News Agency.
The panel found no thrombotic-related reactions following the use of the home-developed Covaxin vaccine, which has administered nearly 19 million doses in India.

Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.